Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Palliative care for diffuse large B-cell lymphoma has significantly improved over the past several years, but disparities ...

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), treatment with fixed-duration Epkinly (epcoritamab-bysp) plus dose-attenuated Rituxan (rituximab) plus cyclophosphamide ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in ...

Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...

In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

Epcoritamab combined with R-mini-CHOP showed a 93% overall response rate in elderly DLBCL patients, with 86% achieving complete response. At two years, 79% of patients remained in response, and 90% ...

NEW YORK, June 27, 2024 /PRNewswire/ -- The global diffuse large B-cell lymphoma (DLBCL) therapeutics market size is estimated to grow by USD 2.24 billion from 2024-2028, according to Technavio. The ...